First Trust NYSE-ARCA Biotechnology
ALTAR
Score™
-0.7% info Recommen-
dation
AVOID
2019E    2020E
P/E
ratio
-194.8x P/Sales
ratio
7.0x
P/BV
ratio
4.9x Div.
yield
0.3%


  • Description
  • Performance
  • Comps
  • premium Fundamentals
  • premium Valuation
  • premium Rating
First Trust NYSE Arca Biotechnology Index Fund seeks investment results that correspond to the price and yield of an equity index called the Amex Biotechnology Index.

FUND BASICS
Category US Equities
Fund Sponsor First Trust Advisors LP
Website www.ftportfolios.com
Inception date Jun 23, 2006
Assets (mns) $1,820
Currency USD
Expense ratio 57 bp
Distributions Quarterly

FUND STRUCTURE
Regulation Open-Ended Fund
Custodian Bank of New York Mellon
Weighting Equal
Index replication Full
Uses derivatives No
Options available Yes

SECTOR BREAKDOWN

 


CONSTITUENT BREAKDOWN
No. of constituents 30
Wgt avg mkt cap (mns) $23,555
Large cap (>$10bn) 47.7%
Mid cap ($2-10bn) 46.3%
Small cap (<$2bn) 6.0%
Developed mkts 100.0%
Emerging mkts 0.0%

TOP TEN HOLDINGS
INTERCEPT PHARMACEUTICALS IN 4.6 %
QIAGEN NV 4.1 %
ALNYLAM PHARMACEUTICALS INC 4.1 %
BIOGEN IDEC INC 3.8 %
SEATTLE GENETICS INC 3.8 %
ACADIA PHARMACEUTICALS INC 3.6 %
SAREPTA THERAPEUTICS INC 3.6 %
VERTEX PHARMACEUTICALS INC 3.5 %
REGENERON PHARMACEUTICALS 3.5 %
AGIOS PHARMACEUTICALS INC 3.5 %
Total 38.2 %

TOP COUNTRY EXPOSURE
UNITED STATES 89.5 %
NETHERLANDS 4.1 %
IRELAND 3.2 %
SPAIN 3.1 %







HISTORICAL PERFORMANCE info

  Custom date range Compare to  
  thru


Standardized Annual Returns (thru November 30)
Year-to-date 1 year 5 years 10 years Since Incep.
18.3% 4.9% 7.6% 18.5% 16.0%

Market Correlations
versus... Beta R-squared
S&P500 1.50 58%
MSCI EAFE 1.28 35%
MSCI Emg. Mkts. 1.08 41%

Technical Indicators
Recent close $148.55
30d moving avg. $140.51
Annualized volatility 23.7%
Short interest (ETF) 0.1%
Short interest (Underlying) 7.1%
Relative strength (RSI) 74

Liquidity measures
Avg. volume (thou.) 96
Turnover 0.8%
Bid/Ask (% of price) 0.09%
ADV underlying (mns) $4,616

Distributions


FINDING ALTERNATIVE FUNDS

Below is a list of 20 potential alternatives to the First Trust NYSE-ARCA Biotechnology ETF based on the alternatives' overlap in portfolio holdings with FBT. Consider funds with lower expense ratios and/or higher ALTAR Score™ ratings as possible alternatives.

Benchmark ticker: FBT Expense: 57 bp ALTAR Score™: -0.7%


ALTERNATIVE ETFs BASED ON OVERLAP WITH FBT
Ticker Fund
Name
Overlap1
vs FBT
(%)
Expense
ratio
(bp)
Savings
vs FBT
(bp)
ALTAR
Score™
(%)
ALTAR
vs FBT
(%)
BBH VanEck Vectors Biotech 61.6 35 22 4.5 +5.3
BBP BioShares Biotech Products 49.2 79 -22 -3.7 -2.9
IBB iShares NASDAQ Biotechnology 43.2 47 10 0.4 +1.1
XBI SPDR S&P Biotech ETF 36.5 35 22 -4.4 -3.6
IEIH iShares Evolved U.S. Innovative Healthcare 27.6 18 39 4.3 +5.1
GNOM Global X Genomics & Biotechnology 26.7 68 -11 -5.3 -4.5
BTEC Principal Healthcare Innovators Index 24.3 42 15 -4.2 -3.5
IDNA iShares Genomics Immunology and Healthcare 23.4 47 10 -4.3 -3.6
LNGR Global X Longevity Thematic 19.7 50 7 3.3 +4.1
FXH First Trust Health Care Alphadex 19.6 63 -6 7.0 +7.8
RYH Invesco S&P Equal Weight Healthcare 15.8 40 17 7.0 +7.7
QQXT First Trust NASDAQ-100 Ex-Tech 15.8 60 -3 5.8 +6.5
SBIO ALPS Medical Breakthroughs 15.6 50 7 -5.0 -4.3
JHMH John Hancock Multifactor Health Care 15.2 40 17 6.6 +7.3
IYH iShares US Healthcare 15.1 43 14 6.2 +6.9
CNCR Loncar Cancer Immunotherapy 14.4 79 -22 -3.5 -2.7
FHLC Fidelity MSCI Health Care 14.1 8 49 5.7 +6.5
VHT Vanguard Health Care 14.1 10 47 5.8 +6.6
PJP Invesco Dynamic Pharmaceuticals 14.1 56 1 9.2 +9.9
PBE Invesco Dynamic Biotechnology & Genome 14.0 57 0 -0.5 +0.2

1Overlap is the percentage of holdings by weight that are identical. For example, if Fund A has a 2% position in Apple, Inc. (AAPL) and Fund B has a 5% position, their overlapping position in AAPL is 2%.

Content on this tab for subscribers only**

RESULTS & ESTIMATES

  2014 2015 2016 2017 2018 2019E 2020E
Sales per share ** ** ** ** ** ** **
Earnings per share ** ** ** ** ** ** **
Dividends per share info ** ** ** ** ** ** **
Book value per share ** ** ** ** ** ** **

 

Sales per share growth   **% **% **% **% **% **%
EPS growth   **% **% **% **% **% **%

Sales per share growth   **% **% **% **% **% **%
EPS growth   **% **% **% **% **% **%

OTHER FUNDAMENTAL METRICS

Long term EPS growth est. **%   Debt-to-equity **x
Asset turnover **%   Assets-to-equity **x

Return on equity

Revision activity*
*Six months ago = 100

Net margins

Compound annual growth rates

Content on this tab for subscribers only

VALUATION METRICS
  2018 2019E 2020E
Price-to-sales ** ** **
Price-to-earnings ** ** **
Price-to-cash flow ** ** **
Price-to-growth ** ** **
Price-to-book value ** ** **
Yield ** ** **

Historical valuation trends

Forward
multiple:
First Trust NYSE-ARCA Biotechnology
Relative
to:
S&P500 MSCI EAFE MSCI Emg. Mkts. Other ETF:

AVOID

Not worthwhile for most investors. A rating of AVOID is assigned to ETFs with ALTAR Scores in the lowest quintile (the bottom 20%) of their category. Often, funds in this category consist of stocks with little if any history or expectation of profitability, and as a result our fundamentally-driven analysis may not be relevant.

ALTAR Score™


Calculation of ALTAR Score™
Avg. Return on Equity -0.8 %
Divided by: Fwd. P/BV 4.9 x
Less: Expense ratio 57 bp
Equals: ALTAR Score -0.7 %
info More information on ALTAR Score™

MODERN PORTFOLIO THEORY info

CONSENSUS RECOMMENDATIONS: FUND CONSTITUENTS
COMPOSITE
RATING
1.41 CATEGORY
AVERAGE
1.56
 
The composite rating is a weighted average of analysts' consensus recommendations for individual ETF constituents, based on the following scale:

BUY = 1; OVERWEIGHT = 1.5, HOLD = 2; UNDERWEIGHT = 2.5; and SELL = 3.

Readers are cautioned that because analyst ratings tend to be inflated, the composite score may be more useful as a relative measure of sentiment between funds rather than as a stand-alone recommendation.
 

 

See RATING tab for calculation of ALTAR Score™
Risk & reward. Uses std. dev. as proxy for risk, ALTAR Score™ for return forecast.
Dividends paid by constituents to the fund. May differ from actual distributions to shareholders due to constituent changes, timing issues or other factors.
Monthly returns based on changes in price plus dividends. May differ from daily returns reported by funds. See below for standardized returns.